Embark Early Education Ltd
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1993-01-01
- Employees
- 5.1K
- Market Cap
- $1.3B
- Website
- http://evotec.com
- Introduction
Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.
Kazia Therapeutics Provides Update on Paxalisib Regulatory Pathway Following Type C Meeting
Kazia Therapeutics provided a regulatory update on paxalisib for glioblastoma treatment after a Type C meeting with the FDA. The FDA suggested OS data supports standard approval, not accelerated. Kazia plans a pivotal Phase 3 study, aligning with FDA on design aspects. Paxalisib also shows promise in pediatric brain cancer and breast cancer treatments.
Pharmaceutical Water Market Size, Share | CAGR Of 9.3%
The Global Pharmaceutical Water Market is projected to grow from US$ 38.6 billion in 2023 to US$ 93.9 billion by 2033, at a CAGR of 9.3%. Growth is driven by demand for high-quality water in drug production, strict regulations, and innovations in water purification technologies. North America leads the market, while Asia Pacific is expected to see the highest growth rate.
Antimicrobial Peptides Market Growth Fueled by Biotechnology
The Global Antimicrobial Peptides Market is projected to grow from US$223.90 Mn in 2023 to US$532.02 Mn by 2031, driven by biotechnology advances and health awareness. Key players include Novozymes A/S, Pfizer Inc., and GlaxoSmithKline plc. Challenges include stringent regulations and microbial resistance.
Evotec And Novo Nordisk Launch Projects For LAB EN² Drug Discovery Accelerator
Novo Nordisk and Evotec select three projects for LAB eN², focusing on cardiometabolic diseases. LAB eN² expands to include Boston Children's Hospital, Johns Hopkins University, and others. The initiative leverages Evotec's R&D platform and Novo Nordisk's disease expertise for drug discovery.
Oncology Based In-vivo CRO Market Size Report, 2025 – 2034
The global oncology-based in-vivo CRO market was valued at USD 1.4 billion in 2024 and is expected to grow at an 8.8% CAGR from 2025 to 2034, driven by demand for immuno-oncology therapies, advancements in in-vivo models, and growing oncology drug approvals from small biotech and pharmaceutical companies. Small firms lead in oncology drug approvals, focusing on innovative treatments like CAR-T cell therapy and monoclonal antibodies. The market is segmented by service, model, end use, and region, with preclinical testing dominating. Key trends include the rise of immunotherapies, outsourcing by biotech firms, AI integration, and strategic alliances between companies and CROs.
Evotec SE announces first projects for LAB eN(2) drug discovery accelerator with Novo Nordisk
Evotec SE and Novo Nordisk select first three projects for LAB eN² drug discovery accelerator, focusing on cardiometabolic diseases from Boston University, Harvard University, and Joslin Diabetes Center. The program expands to include five new academic institutions, offering initial Discovery Award funding and potential additional funding up to IND application stage, with Novo Nordisk maintaining the option to further develop and license specific programs.
Coulter Partners Recruits CEO and Chief Business Officer for IMU Biosciences
Coulter Partners recruited John Baker as CEO and Jason Brown as CBO for IMU Biosciences, with founder Adam Laing transitioning to president and CSO. Baker, formerly of Abcam, and Brown, from Evotec, aim to advance IMU's immune profiling technology for precision medicine.
Halozyme's €2 billion bid to transform drug discovery
Halozyme Therapeutics offers €2 billion to acquire Evotec SE, aiming to combine Halozyme’s drug delivery expertise with Evotec’s drug discovery capabilities, accelerating biologic drug development and expanding global access to affordable treatments. The acquisition, backed by Halozyme’s strong financial position, targets faster market delivery of breakthrough therapies and addresses unmet medical needs in oncology, neurology, and infectious diseases.
© Copyright 2025. All Rights Reserved by MedPath